Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Marine boot Camp might be a another good example.
here is a reasonable opinion:
if you like this stock, keep it or buy more
if you dont:
sell it or go short
the constant back and forth has gotten ridiculous
Any rational-fact based assessment of what T/F happened to AVXL SP (cause) today? TIA
ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and recently a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease.
Thanks , georgejji
recent Form-4 that was filed on 1/12 by Anavex PFO/treasurer?
Maybe my expectations were set higher than they should have been. I really thought this was going to be a very good day but, it was a disappointment. I believe the work has been/is being done but not seeing timely results??? Big Gap.
Thx to Steady_T...on Anavex Life Sciences Corp
Thanks Falconer...
Data from the ANAVEX^2-73-AD-004 trial to be published in an upcoming peer-reviewed
journal
Nothing conjectural or indecisive about this statement; "...to be published...."
Steady_T: You might add, ["This is a drill. No live ammunition will be fired. This is a drill." "This is a drill. No live ammunition will be fired. This is a drill. quote]...Roger that
Now set At SFO launch time +1:00 hr. Prepare the flight deck for air operations.
Look at the bright side. You never hear the one that kills you. WGT.
Many here have been around AVXL for years, like I have. If we were right to stick around and pray then I guess we will get rewarded. Current and (potential) future CNS disease patients will/should be better off , along with us if we were right to hang on. Good Luck to all, no going back after today, IMO.
Fumbles on the one yard line.
Kentucky123
Curious if others think AVXL , "sticks this landing" , during Thursday's JPM conference? We are due, we are on the downwind leg about to turn base . Crowd thinks we are cleared to land, w/full stop. Do not want to see another,..."touch and go"...
AND...BTW, are you still beating your dog? TIA, jfk
Looking fwd to a good day.
Cpap21...
Can someone give some thoughts on what our CEO is going to present tomorrow?
test...new thoughts on what JPM-AVXL brings to surface? For example: Will FDA finally (please) abandon the entire Amyloid-AD thesis?
This was recently posted on Dr Alan Green's website: rapamycintherapy.com:
"Hypertrophic cardiomyopathy. Cured by Rapamycin.
1% sudden death per year. Only treatment, defibrillator.
Progresses to fibrosis, heart failure, death. Most common inherited cardiomyopathy."
"A patient, middle age Ophthalmologist being followed by a Cardiologist.
Takes Rapamycin. Echocardiogram every year. Each year less and less obstruction, and thickening.
After 3 years, has melted away. Heart looks normal, shortness of breath on exertion gone. Person who does Echocardiogram each year says this is impossible."
If this is truly an effect of the rapamycin therapy, then given the similar molecular structure and docking site of A 2-73 to rapamycin (per georgejjl), might A 2-73 have even more therapeutic application than already disclosed?
I agree ,
Anavex has done some nice work trying to understand how this works and I believe it’s all part of the strategy of precision medicine and the use of biomarkers and the collection of all data in case an argument needs to be made[/quote] by Jimbo50....Nidan says , I believe AVXL will soon supplement the AVXL home base of information while connecting the AI Dot portfolio from S1R links.
Firstly, let's get A2-73 approval for RETT which will set the stage for those HUGE revenues.
IMO, these exact scenarios/facts will be used in future graduate school CASE BOOK STUDY EXAMPLES to illustrate FDA weaknesses and poor reasoning guidance.
About Neurodevelopmental Disorders
Neurodevelopmental disorders refer to a group of conditions that affect the way the brain and nervous system develop. These disorders can cause changes to thinking, feeling, language, and physical abilities like movement and coordination. Neurodevelopmental conditions typically start before adulthood and may continue into adulthood. They are often associated with social impairments and difficulties in communication. [1] The number of people globally with developmental intellectual disability was estimated at 107.62 million according to IHME, Global Burden of Disease (2019). [2]
So would this be something that they are doing so they can go after a basket trial, or go to the FDA with enough data that says if these McCp2 conditions exist use Anavex 2–73?
Y=Yes=Excellent.
tradeherpete...now I'm confused ...do you support AVXL (Y? N?) ...TIA.
bas2020
t would be a true disappointment and failure if the endpoints missed an expectedly "normal" placebo response of little to no improvement. If the placebo response was "normal", blarcamesine would've clearly exceeded in meeting endpoints and the trial would've been a resounding success.
Obviously, that didn't happen. Instead, the trial got hit with some unfortunate bad luck with extraordinary placebo scores. However, it's not the first time a Rett trial has experienced this... and the reasons behind it are quite plausible. It's not a true placebo effect with the patient, where the patient realizes s/he is taking a drug and believes it's helping him/her. Rather, it's one that's expressed and influenced by the parents/caregiver... and that positive "hope" and belief are conveyed to other Rett parents, as well as the reviewers. It's rather normal for this "bias" to happen... more so with pediatric patients than with aging AD patients.
It's not the first time the FDA has experienced this phenomena... and is why they frequently approve a drug in these circumstances, especially a safe drug. They review the entire package of trial data, OLE and REW information in the approval process... not just the p-values.
Not concerned at all about the prospects of approval for Rett... and AD.
powerwalker
plex, first, thanks for your kind comments. Yes, I'm still a strong WGT proponent, regardless of the Rett upset. I don't give up on my team because they lost one (Notre Dame v. Purdue, 1977).
I know it might be hard for Dr. Missling to admit and change course, but I think he and Anavex need to be more upfront and transparent as I noted yesterday in the post below:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173570974
There is probably more hope in that post than reality of a change at Anavex. But, TGD must be more disappointed than those supporters of WGT are and might be that a re-think is in order and that a little more openness might be affordable.
TGD must be more disappointed than those supporters of WGT are and might be that a re-think is in order and that a little more openness might be affordable.
bas2020
Not a waste of time if the FDA is impressed by the complete package of trial data, OLE and RWE evidence. Agree... AD is priority #1, but that doesn't mean drop Rett.
georgejji
Prediction regarding the AVXL stock price next week:
The AVXL stock price will be significantly higher next week than it is this week and it will be significantly higher within 2 weeks than it will be next week.
ANTICIPATION OF THE PEER REVIEWED PAPER REGARDING THE PHASE 2B/3 TRIAL FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH BLARCAMESINE.
Good luck and GOD bless,
There is some huge money behind these guys.
The JP Morgan conference timing next week provides a SP reset period for those who are trying to drive SP down right now, IMO. I am looking for AVXL to show a good projection which will more than off set where we are today. IMO, current SP reset is unwarranted and is in anticipation of that.
Someone is very worried-concerned about AVXL trial successes. IMO. They know their clock is running.
a confirmation study if they can be covered by a potential partnership fee or conditional approval revenue
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease.
https://www.anavex.com/post/anavex-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference?mc_cid=a6f12dda91&mc_eid=a2160c00e9
[quoteThe CGI-I p value of 0.063 is close enough for approval along with the remainder of the NDA in order for the FDA to grant approval to Anavex for blarcamesine to treat Rett syndrome.
1-p= 93.7% which is very good.][/quote]georgejji
Is there any clinical results/ trials point #CGI-I where adult family members (parents for example ) would be allowed to make a go-no go use decision for their child?
bas2020
I think we'll see a PR right before the conference.
If you like/agree w/Dr.M.'s style or methods we must agree the guy has guts. He is going into the opponents kitchen and flipping them the bird w/the plans for next weeks J.P.M. conference. These are the actions of a guy who is committed to the mission , not someone who is standing on the sidelines while others take the risks and heat. IMO, those who have been there, know it when they see it.
IMO, he is doing the right thing. He has BP/WS opponents who wish him boundless (unwell) but he going to take the hill anyways. IMO, the U.S. drug development system is not effective b/c such work cannot be done unless informed risks are taken as appropriate. He presents the spirit of a warrior, Semper fi, dude.]
"NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Anavex’s President and Chief Executive Officer, Christopher U Missling, PhD, is scheduled to present at the conference at the Westin St. Francis in San Francisco, CA on January 11, 2024 at 10:30am Pacific Standard Time (PST)."
YA THINK???Pesky facts and judgment application. THX...